EFFICIENCY OF LOW DOSE 30MCI OF I-131 FOR LOW TO INTERMEDIATE RISK THYROID CANCERS USING TRIPLE NEGATIVE CRITERIA
DOI:
https://doi.org/10.55519/JAMC-01-12782Keywords:
Differentiated thyroid cancers (DTC); Radioiodine ablation (RAI)Abstract
Background: Radioiodine-131 ablation (RAI) of residual functioning thyroid tissue is a staple in the treatment of many Thyroid Cancer patients after surgery. However, it is debated and reexamined to avoid overtreatment of low-risk carcinomas and improve the detection of tumors that are more aggressive. We determined the difference in treatment response during one year after ablation. Moreover, we investigated differences between patients who did not undergo RAI Treatments and compared them to patients receiving a low dose of iodine (30 mCi). Methods: This was a retrospective study conducted at Aga Khan University Hospital (AKUH) in Karachi, Pakistan. The study population was patients with low to intermediate risk of well Differentiated thyroid cancers (DTC). A descriptive analysis was done. Categorical variables were represented as frequencies and percentages. The comparison was done by Chi-square. Results: Out of 102 participants, mean age was 41.88 years and the majority were females (73.5%). The common diagnosis was papillary thyroid carcinoma (84.3%). A low recurrence risk was reported in 89.2%. 98% of patients were given a 30-mci dose of RAI. The majority 83.3% of participants reported a Post-ablative Whole-body iodine scan (WBIS) showing no distant metastasis 1 year after RAI ablation. 55.8% of participants reported an excellent response to treatment, followed by 17.65% of participants having incomplete biochemical responses. Conclusion: This study concludes that a low dose of RAI provided an excellent response to treatment in contrast to patients who had no RAI dose. After 1 year of follow-up, ultrasound imaging showed negative structural recurrence in the majority of patients which proves that a low dose of RAI can help for a disease-free follow-up.
References
1. Zaman MU, Fatima N, Padhy AK, Zaman U. Controversies about radioactive iodine-131 remnant ablation in low risk thyroid cancers: are we near a consensus? Asian Pac J Cancer Prev 2013;14(11):6209–13.
2. Schwengber WK, Mota LM, Nava CF, Rodrigues JAP, Zanel-la AB, Kuchenbecker RDS, et al. Patterns of radioiodine use for differentiated thyroid carcinoma in Brazil: insights and a call for action from a 20-year database. Arch Endocrinol Metab 2020;64(6):824–32.
3. Andresen NS, Buatti JM, Tewfik HH, Pagedar NA, Anderson CM, Watkins JM. Radioiodine ablation following thyroidec-tomy for differentiated thyroid cancer: literature review of utility, dose, and toxicity. Eur Thyroid J 2017;6(4):187–96.
4. Iconaru L, Baleanu F, Taujan G, Duttmann R, Spinato L, Karmali R, et al. Can we safely reduce the administration of 131-iodine in patients with differentiated thyroid cancer?–experience of the Brugmann hospital in Brussels. Thyroid Res 2020;13:15.
5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nod-ules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and dif-ferentiated thyroid cancer. Thyroid 2016;26(1):1–133.
6. Gómez-Pérez AM, García-Alemán J, Molina-Vega M, Sebas-tian Ochoa A, Perez Garcia P, Mancha Doblas I, et al. Effica-cy of low-dose radioiodine ablation in low-and intermediate-risk differentiated thyroid Cancer: a retrospective compara-tive analysis. J Clin Med 2020;9(2):581.
7. Fatima N, Zaman A, Zaman U, Tahseen R. Comparable abla-tion efficiency of 30 and 100 mCi of I-131 for low to inter-mediate risk thyroid cancers using triple negative criteria. Asian Pac J Cancer Prev 2016;17(3):1115–8.
8. Kim K, Bae JS, Kim JS. Long-term oncological outcome comparison between intermediate-and high-dose radioactive iodine ablation in patients with differentiated thyroid carci-noma: a propensity score matching study. Int J Endocrinol 2021;2021:6642971.
9. Súss SKA, Mesa Jr CO, Carvalho GAd, Miasaki FY, Chaves CP, Fuser DC, et al. Clinical outcomes of low and intermedi-ate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy. Arch Endocrinol Metab 2018;62(2):149–56.
10. Faro FN, Bezerra ÂMLB, Scalissi NM, Cury AN, Marone MM, Ferraz C, et al. Intermediate-risk thyroid carcinoma: in-dicators of a poor prognosis. Arch Endocrinol Metab 2020;64(6):764–71.
11. ElSaedy M, Daoud M, Sakr H, Rashed H. Effect of Different Ablative Doses of Radioactive Iodine in Patients with Differ-entiated Thyroid Carcinoma and Cervical Lymph Node Me-tastasis. SECI Oncol 2023;2:131–8.
12. Wongsurawat N, Somboonporn C, Raruenrom Y, Thinkhamrop B. Low versus high 131I therapeutic effective-ness for differentiated thyroid cancer with intermediate risk of recurrence. Asia Pac J Sci Tech 2021;27(4):1–10.
13. Li F, Li W, Gray KD, Zarnegar R, Wang D, Fahey TJ 3rd. Ablation therapy using a low dose of radioiodine may be suf-ficient in low-to intermediate-risk patients with follicular variant papillary thyroid carcinoma. J Int Med Res 2020;48(11):0300060520966491.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Asifa Jamali, Nanik Ram, Farah Khalid, Mabrooka Kazi, Najmul Islam
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
